 Activation of p53 protein by telomeric (TTAGGG)ₙ repeats

Michael Milyavsky¹, Avishai Mimran¹,², Shai Senderovich¹, Irit Zurer¹, Neta Erez¹,², Igor Shats¹, Naomi Goldfinger¹, Irun Cohen² and Varda Rotter¹,*

¹Department of Molecular Cell Biology and ²Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel

Received June 18, 2001; Revised and Accepted October 24, 2001

ABSTRACT

Genome instability is a primary factor leading to the activation of the p53 tumor suppressor protein. Telomeric repeat (TR) sequences are also responsible for genome integrity. By capping the termini of the chromosomes, TRs prevent them undergoing nucleolytic degradation, ligation or chromosome fusion. Interestingly, telomere shortening was suggested to activate p53, which in turn may cause primary cells to senesce. In order to elucidate the nature of a possible cross talk between the two, we introduced into cells TRs of defined length and investigated their effect on p53 activation and subsequent cellular response. We found that the introduction of a TR into cells leads to stabilization of the p53 protein. This stabilization was specific to TRs and was not observed in response to exposure of cells to plasmids containing non-TR sequences. p53 stabilization requires the presence of an intact p53 oligomerization domain. TR-activated p53 exhibited enhanced transcriptional activity. Eventually, TRs induced p53-dependent growth suppression, measured as a reduction in colony formation.

INTRODUCTION

Both p53 protein and telomeres play a pivotal role in the maintenance of genome stability. Each one of them was shown to be associated with DNA repair pathways and genomic integrity checkpoints; therefore, both could be regarded as guardians of the genome (1). Telomeres are nucleoprotein structures found at the ends of eukaryotic chromosomes. In humans, the telomeric DNA consists of 5–15 kb of (TTAGGG)ₙ repeats (2). Telomere structure and function are regulated by a number of telomeric DNA binding proteins; the main ones are telomeric repeat binding factors (TRF)-1 and TRF-2 (3). Both telomeric DNA and trans-acting protein factors evolve in solving the end replication problem (4–6), protection of chromosome ends from recombination, fusion and degradation (7), and finally, prevent the chromosome ends from being recognized as damaged DNA. Each replication cycle of human primary somatic cells is associated with the loss of 50–150 bp of telomeric repeat (TR) DNA (8–10) and thus in the absence of specific repair mechanism, primary somatic cells stop proliferating when critical telomere length is reached (5,11). This irreversible cell-cycle arrest, termed replicative senescence, is mainly attributed to wild type p53 tumor suppressor activation (12–16). Exposure of chromosome ends and telomeric single-strand damage were recently shown to induce p53-dependent apoptosis or growth arrest, respectively (17). However, the molecular mechanism that underlies p53 activation under these circumstances is still unknown.

The p53 tumor suppressor is a multifunctional protein, which by exerting a variety of activities in the cell has a critical role in protection from cancer development (18–20). The protein, which is a transcription factor, binds the consensus DNA sequences of p53-specific target genes through the core domain and activates transcription through its N-terminus (21). The C-terminus of the protein is considered to be a regulatory domain, which contains several sites for post-translational modifications (22,23). It is well accepted that the main function of the p53 protein is to respond to damaged DNA through several pathways (24). Transcription activation of p21⁰⁰⁰ and GADD45 leads to G1 cell-cycle arrest and DNA repair (25,26), whereas transcriptional activation of BAX and several other pro-apoptotic genes, may lead to p53-dependent apoptosis (27–32). In addition to sequence-specific DNA binding, p53 was also shown to interact with different types of damaged DNA. The C-terminus domain recognizes double-stranded and single-stranded (ss) DNA ends, internal deletion loops in DNA and helps catalyze the annealing of ssDNA to double strands (33–37). This recognition of damaged DNA may facilitate the activation of p53 sequence-specific DNA binding. A signaling cascade of p53 activation in response to DNA damage involves multiple post-translational modifications of the molecule. These include phosphorylations that are mediated by ataxia telangiectasia mutated (ATM) (38) and/or DNA-phosphatidylinositol 3 kinase (PK) (39) and p300-mediated acetylations (23,40,41). Those modifications are believed to relieve Mdm-2-mediated degradation (39), which allows effective accumulation of a transcriptionally active p53.

Inactivation of the p53 pathway was suggested to account for the escape from replicative senescence that is associated with critical telomere length (12–16). In contrast to normal cells, immortalized cells maintain their telomeres in order to keep a certain level of genomic stability by two means. One pathway that is predominantly used by immortal and cancer cells
engages the action of the reverse transcriptase enzyme telomerase (42–45). The second pathway, alternative lengthening of telomeres (ALT), is a less frequently used mechanism based on recombination (46,47).

Our present study was addressed at the elucidation of the relationship between p53 and TRs. To that end, we have exposed the p53 protein to telomeric sequences either by cotransfection of the wild type p53 expression vectors and TR-containing plasmids into p53 null cells or by transfection of TR-containing plasmids into cells expressing endogenous wild type p53 protein. We found that TRs induced the stabilization of both exogenous and endogenous p53 proteins as compared with controls. Furthermore, the extreme C-terminus of p53, which was shown to be the non-specific DNA-binding domain, was found to be dispensable for stabilization induced by TRs, whereas the oligomerization domain was essential. The TR-stabilized p53 exhibited an enhanced transcriptional activity. Finally, activation of p53 by a TR-containing plasmid was associated with significant suppression of colony formation of a cell line containing functional p53. Inactivation of p53 by E6 oncoprotein abrogated this growth suppression effect. This suggests that TR sequences are important constituents of a novel pathway leading to p53 protein activation.

MATERIALS AND METHODS

Cell lines

H1299 cell line (ATCC number: CRL-5803) is a human non-small cell lung cancer, lacking p53 expression due to a 5′-intragenic deletion (48). The cell line was maintained in RPMI medium supplemented with 10% fetal calf serum (FCS). MCF-7 breast cancer cell line (ATCC number: HTB-22) and Hep G2 hepatoblastoma cells (ATCC number: HB-8065) were grown in DMEM supplemented with 10% FCS, 1.0 mM sodium pyruvate and 2 mM L-glutamine. WI-38 mortal cell line (ATCC number: CCL75) derived from a human embryonic lung was grown in MEM supplemented with 10% FCS, 1.0 mM sodium pyruvate and 2 mM L-glutamine. HCT116 colon cancer cells were the kind gift of Dr B. Vogelstein (The Johns Hopkins Oncology Center) and were grown in McCoy medium supplemented with 10% FCS and 2 mM L-glutamine. HEP G2 hepatoblastoma cells (ATCC number: HB-8065) were grown in RPMI medium supplemented with 10% FCS, 1.0 mM sodium pyruvate and 2 mM L-glutamine. HCT116 colon cancer cells were the kind gift of Dr B. Vogelstein (The Johns Hopkins Oncology Center), p53-360-del and 342-stop were described previously (49). The reporter plasmids used were Waf-1-Luc, Mdm-2-Luc, p53-240-Stop and p53-360-Del (49).

The reporter plasmids used were Waf-1-Luc, Mdm-2-Luc, Bax-Luc (provided by Dr M. Oren, Weizmann Institute of Science).

pBlueScript-TEL was generated by the subcloning of telomere repeats (TTAGGG)40 insert (240 bp) from pHuR93 plasmid (50) into the PstI site of the pBlueScript. Plasmids containing T2AG3, T2AG2Ca and T2AG5 repeats were cloned into pSX-neo vector and were kindly provided by Dr T. de Lange (The Rockefeller University).

pCMV-Neo-Bam-p53 was kindly provided by Dr L. Sherman (Tel-Aviv University). All plasmids were purified by Quigen Plasmid Purification kit using the manufacturer’s provided protocol.

DNA transfections

Cells were grown in a complete medium and replated 16–24 h before transfection. For reporter gene assay and protein levels, study cells were transfected by FuGENE 6 Transfection Reagent (Boehringer Mannheim). DNA precipitates were left on the cells for 24 h, after which fresh complete medium was added for the periods indicated. HCT116 cells were transfected by Lipofectamine reagent (Life Technologies). Precipitates were left on the cells for 6 h, after which fresh complete medium was added.

Colony formation assay

HCT116 cells were replated 16–24 h before transfection in 10-cm dishes. The cells were transfected by Lipofectamine (26 μl) with pBlueScript, pBlueScript-TEL or their mixture as indicated. Two micrograms per plate of E6 expression plasmid (when indicated) and 1 μg/plate of pBabe-puro were included. A constant amount of DNA (13 μg/transfection) was maintained. Transfections were performed in a total volume of 6 ml serum-free DMEM medium. Six hours later, the serum-free medium was replaced by DMEM medium supplemented with 10% FCS. Forty-eight hours after transfection, cells were trypsinized and 1 × 105 cells plated out into medium containing puromycin (1 μg/ml). Sixteen days later, plates were fixed, stained with Crystal Violet and colonies were counted.

Western blot analysis

Nuclear extracts were prepared by a modified protocol according to that described before (51). Briefly, 105–106 cells were washed twice with cold phosphate-buffered saline (PBS), cell pellets were resuspended in 400 μl buffer A [10 mM HEPES–KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCI, 0.5 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml leupeptin, 1 μg/ml pepstatin and 10 μg/ml aprotinin] by gentle pipetting. After 15 min incubation on ice, 25 μl of 10% NP-40 was added and vortexed vigorously for 10 min. After centrifugation, cell pellets were resuspended in 150–300 μl of buffer C (20 mM HEPES–KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml pepstatin and 10 μg/ml aprotinin). Tubes were transferred to a rotating platform for 15 min at 4°C. After centrifugation the supernatant was kept at −70°C. Extracts were analyzed for protein concentration (Bradford assay).

For total cellular extract, 106 cells were lyzed in sample buffer (140 mM Tris pH 6.8, 22.4% glycerol, 6% SDS, 10% β-mercaptoethanol and 0.02% bromophenol blue) boiled and loaded on 10% polyacrylamide gels containing SDS. Proteins were transferred to nitrocellulose membranes. The p53 protein was detected using p53 monoclonal antibodies: DO-1, PAB-1801 and PAB-421. Anti-p21 antibody (C-19) was purchased from Santa Cruz. The protein–antibody complexes were detected using a horseradish peroxidase (HRP)-conjugated secondary antibody using the super-signal enhanced chemiluminescence system (Pierce).
Luciferase assay

For luciferase assays, MCF-7 and H1299 cells were seeded in 12-well plates or WI-38 cells were seeded in 6-well plates and transfected with 200 ng of different p53-responsive luciferase constructs, 5 ng of p53 expression vector, 200 ng of cytomegalovirus (CMV) β-galactosidase expression vector and increasing amounts of pBlueScript-TEL. The total amount of DNA in each transfection was kept constant by complementing with pBlueScript vector control DNA. After 24–48 h the cells were rinsed twice with cold PBS and lysed in the wells by cell culture lysis reagent (Promega) for 15 min at room temperature. A sample (100 µl) of lysate was quantified for luciferase activity in the presence of luciferin (Promega) and ATP using a Turner Design Model 20 Luminometer. Transfections were done in triplicate and normalized to β-galactosidase activity as an internal transfection control.

β-Galactosidase enzyme assay

A sample (10–15 µl) of cell lysate was mixed with 100 µl of Lac Z buffer (60 mM Na2CO3, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) and 20 µl of substrate [2 mg/ml o-nitrophenol-β-D-galactopyranoside (ONPG) in Na2CO3, 40 mM NaH2PO4]. The reaction was incubated at 37°C until a yellow color was visible and stopped by the addition of 1 M Na2CO3. The results were read at OD420 using a multi-well ELISA reader.

RESULTS

We were interested in studying the effect of a defined telomeric DNA sequence on the p53 protein, which potentially can recognize DNA both in a sequence-specific and non-sequence-specific manner (22). In designing our experiments we considered the observations that the treatment of cells with oligonucleotides, linearized plasmid DNA, circular DNA with a large gap or single-stranded circular phagemid, can all activate p53 and induce a p53-dependent growth arrest. Supercoiled and nicked plasmids that lack free ends of DNA were ineffective (52). In the above experiments, p53 activation was attributed to the disruption of the p53–Mdm-2 interaction that leads to attenuation in the degradation process (49).

To examine the possibility that TRs induced p53 protein stabilization. H1299 p53 null cells were transiently co-transfected with p53 expressing plasmid in the presence of pBlueScript, pBlueScript-TEL or their mixture as indicated in the table. Constant amount of DNA (10 µg/transfection) was maintained. Twenty-four hours later, the p53 protein level was determined by western blotting using DO-1 monoclonal antibody. Comparable loading is demonstrated by β-tubulin blotting. (B) Stabilization of endogenously expressed p53 by TR sequences. HepG2 (a, upper panels) or MCF-7 (b, lower panel) cells were transiently transfected with 20 µg of either pBlueScript or pBlueScript-TEL. Forty-eight hours later, p53 levels were determined by western blotting with the indicated anti-p53 monoclonal antibodies. NT, non-treated cells.

TR sequences induce p53 protein stabilization

An important manifestation of the activation of p53 is an increase in protein level. In unstressed cells, the p53 protein is barely detectable and has a very short half-life. This is due to rapid degradation via the Mdm-2 ubiquitin–proteasome pathway (56,57). However, in response to genotoxic stress or hypoxia p53 rapidly accumulates. This stabilization is mostly attributed to the disruption of the p53–Mdm-2 interaction that leads to attenuation in the degradation process (49).

For luciferase assays, MCF-7 and H1299 cells were seeded in 12-well plates or WI-38 cells were seeded in 6-well plates and transfected with 200 ng of different p53-responsive luciferase constructs, 5 ng of p53 expression vector, 200 ng of cytomegalovirus (CMV) β-galactosidase expression vector and increasing amounts of pBlueScript-TEL. The total amount of DNA in each transfection was kept constant by complementing with pBlueScript vector control DNA. After 24–48 h the cells were rinsed twice with cold PBS and lysed in the wells by cell culture lysis reagent (Promega) for 15 min at room temperature. A sample (100 µl) of lysate was quantified for luciferase activity in the presence of luciferin (Promega) and ATP using a Turner Design Model 20 Luminometer. Transfections were done in triplicate and normalized to β-galactosidase activity as an internal transfection control.

β-Galactosidase enzyme assay

A sample (10–15 µl) of cell lysate was mixed with 100 µl of Lac Z buffer (60 mM Na2CO3, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) and 20 µl of substrate [2 mg/ml o-nitrophenol-β-D-galactopyranoside (ONPG) in Na2CO3, 40 mM NaH2PO4]. The reaction was incubated at 37°C until a yellow color was visible and stopped by the addition of 1 M Na2CO3. The results were read at OD420 using a multi-well ELISA reader.

RESULTS

We were interested in studying the effect of a defined telomeric DNA sequence on the p53 protein, which potentially can recognize DNA both in a sequence-specific and non-sequence-specific manner (22). In designing our experiments we considered the observations that the treatment of cells with oligonucleotides, linearized plasmid DNA, circular DNA with a large gap or single-stranded circular phagemid, can all activate p53 and induce a p53-dependent growth arrest. Supercoiled and nicked plasmids that lack free ends of DNA were ineffective (52). In the above experiments, p53 activation was attributed to the disruption of the p53–Mdm-2 interaction that leads to attenuation in the degradation process (49).

To examine the possibility that TRs induced p53 protein stabilization. H1299 p53 null cells were transiently co-transfected with p53 expressing plasmid in the presence of pBlueScript, pBlueScript-TEL or their mixture as indicated in the table. Constant amount of DNA (10 µg/transfection) was maintained. Twenty-four hours later, the p53 protein level was determined by western blotting using DO-1 monoclonal antibody. Comparable loading is demonstrated by β-tubulin blotting. (B) Stabilization of endogenously expressed p53 by TR sequences. HepG2 (a, upper panels) or MCF-7 (b, lower panel) cells were transiently transfected with 20 µg of either pBlueScript or pBlueScript-TEL. Forty-eight hours later, p53 levels were determined by western blotting with the indicated anti-p53 monoclonal antibodies. NT, non-treated cells.

TR sequences induce p53 protein stabilization

An important manifestation of the activation of p53 is an increase in protein level. In unstressed cells, the p53 protein is barely detectable and has a very short half-life. This is due to rapid degradation via the Mdm-2 ubiquitin–proteasome pathway (56,57). However, in response to genotoxic stress or hypoxia p53 rapidly accumulates. This stabilization is mostly attributed to the disruption of the p53–Mdm-2 interaction that leads to attenuation in the degradation process (49).
significant augmentation of p53 protein levels were evident when HCT116 cells were transfected with control plasmids (pBlueScript and pSx-neo) or with plasmids containing repeats such as, T$_3$AG$_3$, T$_2$AG$_2$C, T$_2$AG$_3$, T$_4$AG$_3$. T$_2$AG$_3$ induced p53 protein exhibited an increased transactivation potential as measured by increased expression of its target gene MDM-2. A similar pattern of preferential induction of p53 protein in response to TR transfection as compared with the non-TR sequences was also observed in the MCF-7 cell line (Fig. 2, bottom panel).

**p53 stabilization in response to TRs requires an intact oligomerization domain**

Stabilization of p53 by various stimuli may involve different mechanisms. We reasoned that identification of the specific p53 domains that are responsible for the stabilization of the molecule in response to TR-containing plasmid would provide us with additional cue(s) concerning the p53-telomere pathway. To this end, we transfected H1299 cells with wild type p53 as well as with two C-terminal deletion constructs together with TR-containing or control plasmids. The p53-360-del construct codes for a p53 protein without the 30 C-terminal amino acids. The p53-342-stop mutant codes for a p53 protein that has a stop codon mutation at the oligomerization domain (59). As seen in Figure 3, pBlueScript-TEL induced the stabilization of the full length as well as that of p53-360-del encoded p53 protein. In contrast, the level of the oligomerization-defective p53 protein, encoded by p53-342-stop, was unchanged.

These results point to the possibility that an intact oligomerization domain of p53 is necessary for this mechanism of p53 stabilization.

**TR sequences enhance p53-dependent transactivation**

In the following experiments we examined whether TR-stabilized p53 protein also facilitates p53 transcriptional activity. To that end, we co-transfected H1299 p53 null cells with the p53 expression plasmids and the Waf-1-Luc or the Mdm-2-Luc in conjunction with the TR-containing plasmids. As seen in Figure 4A, co-transfection of p53 in conjunction with pBlueScript-TEL into H1299 cells significantly enhanced luciferase activity mediated by Waf-1-Luc reporter as compared with cells co-transfected with the control (pBlueScript) plasmid. It should be noted that no effect of either pBlueScript-TEL or pBlueScript was scored when Waf-1-Luc activity was assayed in the absence of p53. Similar patterns of enhancement in the transcriptional activity of p53 by pBlueScript-TEL were also
The presence of extra-chromosomal TRs specifically enhances the transactivation potential of the p53 protein. This was the case both for exogenous and endogenous expressed wild type p53. Moreover, the effect does not seem to be cell type-specific. Indeed, enhancement of the p53 transcriptional activity, mediated by telomeric sequences, was equally evident in epithelial and in fibroblast cells and observed in primary (WI-38) as well as in transformed (H1299, MCF-7) cellular contexts.

Our experiments show that exposure of cells to pBlueScript-TEL plasmid induces an accumulation of both exogenously and endogenously expressed wild type p53 proteins. This stabilization was accompanied by significant up-regulation of the p53 transcriptional activity. Collectively, the data suggest that the TRs would enhance activation of p53 probably by inducing protein stabilization, which in turn may facilitate transcriptional activity.

**TR sequences induce growth suppression in the p53-dependent manner**

The above observations showing that plasmid containing TRs induces p53 protein stabilization and enhances p53-dependent transcription (including the transcription of growth suppressive p21 and pro-apoptotic BAX genes) prompted us to test the effect of telomeric sequence on cell growth and proliferation. For this purpose, we used the HCT116 colon cancer-derived cell line containing wild type p53 as well as functional DNA damage checkpoints (61,62). HCT116 cells were transfected with a mixture of pBlueScript/pBlueScript-TEL plasmids at various ratios. The total amount of transfected DNA was kept constant in all transfections. In agreement with the above observation with other cell lines, increasing amounts of TR-containing plasmid induces p53 protein accumulation, as compared with transfection with a control plasmid. Moreover, this p53 induction was accompanied by significant up-regulation of the p53 transcriptional activity.

In order to monitor the effect of extra-cellular TRs on cell growth in a long-term colony formation assay, we co-transfected puromycin resistance plasmid along with the test plasmids. Following selection the colonies were counted. As seen in Figure 5B, a significant reduction in the number of colonies which correlated with increasing amount of telomeric plasmid DNA was observed. To confirm that the reduction observed in the colony number is indeed a result of p53 activation, we also co-transfected E6 expression plasmid along with the increasing amount of telomeric plasmid. The addition of E6 completely alleviated the TR induced growth suppression effect (Fig. 5B).

The observed suppression in colony formation following transfection of TR sequences is most likely due to the increase in the p53 transcriptional activity observed in the presence of
p21Waf–1 cyclin-dependent kinase inhibitor by p53 accounts for
its direct target p21 was significantly increased (Figs 1 and
3A) following telomeric plasmid transfection. This is in agree-
ment with previous studies demonstrating that induction of
5A) following telomeric plasmid transfection. This is in agree-
ment with previous studies demonstrating that induction of

DISCUSSION
Both p53 and TR sequences were shown to play a pivotal role
in the maintenance of genome stability (1,65). An association
between telomere dysfunction and p53 activation has been
established over the last few years. For example, it was shown
by Chin et al. (66) that growth arrest and apoptosis observed in
the late generations of mTR knockout mice were due to p53
activation. This points to the importance of p53 in a pathway
that underlies the response to telomere dysfunction. Likewise,
it was suggested that the critical shortening of telomeres or
aberrations in their structure might be recognized as DNA
damage by the p53-dependent cell-cycle check point system
(17,67,68). However, the nature of the interaction between TR
sequences and p53 has not been elucidated yet.

Here we report on the observation that TR sequences can
induce p53 activation. We found that transfection of an intact
plasmid containing a 240 bp TR insert induced the activation
of p53 in several cell type systems. Both endogenously and
exogenously expressed wild type p53 were stabilized in the
presence of the pBlueScript-TEL plasmid but not in the
presence of the pBlueScript control plasmid or the plasmids
containing repeats with non-telomeric sequences. TR-activated
p53 exhibited enhanced transcriptional activity and exerted a
growth suppression activity that was manifested by a reduction
in the number of colonies scored in the long-term colony
formation assay.

As it is accepted that broken DNA serves as a DNA insult
that induces stabilization of the p53 protein, we have used in
our experiments circular plasmids that contain the telomeric
repeat sequences. In agreement with others (52) we found that
exposure of cells to telomeric oligonucleotides induced p53
stabilization, as did non-TR sequences. However, we assumed
that probability of random break generated in cells following
DNA transfection is similar with all constructs used. Thus, the
specific response observed in the case of TR (T2AG3)-containing
plasmid is probably not a result of exposure of cells to broken
DNA.

Based on data presented here and that accumulated by others
(1,17,68), we would like to propose several models describing
a plausible cross talk between TR sequences and the p53 tumor
suppressor protein that may in turn lead to the activation of the
latter. One model would suggest a direct recognition of TR
DNA sequence by p53. Another one may engage the existence
of mediator protein(s) or enzymatic activity that anchor p53
onto the telomeres or transmit the signal. A third model, which
may induce p53 activation, consists of a squelching mech-
anism by which exogenously introduced TRs compete out the
endogenous telomeres for TRFs that otherwise suppress p53
activation.

p53 was shown to interact with DNA both through its ‘core’
domain (100–300 amino acids) and its C-terminus. The core
domain of wild type p53 was shown to interact with a specific
‘consensus’ sequence found in p53 target genes that will lead
to the specific transactivation of the latter (19). The C-terminus
was suggested to bind damaged DNA in a non-sequence-
specific manner. Several mechanisms by which alterations at
the C-terminus affect the capacity of the p53 ‘core’ domain to
interact with the p53-specific target genes were proposed. One
of them involves a conformational change of the p53 molecule
driven by its C-terminus domain. Phosphorylations and
acetylations at the C-terminus allow allosteric change of the
whole molecule that enhances specific DNA binding by the
core domain (69). A similar effect can be achieved by the inter-
action of the C-terminus with damaged DNA (37), PAb-421
antibody (70) or C-terminus-derived peptides (71). An
intriguing possibility, pertaining to our present study, is the
observation that enhancement in the p53 transactivation potential
by the presence of TRs is a result of a direct recognition of the
(TTAGGG)ₙ DNA motif by the p53 C-terminus domain. This interaction was suggested to facilitate the conformation conversion of latent p53 molecules into activated ones (72). Furthermore, the ability of the G-rich telomeric sequences to create quaternary structures and loops under physiological conditions (2) could provide an additional target sequence for the p53 C-terminus domain that is known to interact with loops resulting from insertion–deletion mismatching (35). The fact that in our experiments p53 protein deleted of its C-terminus is still activated by the TR suggests that this domain is not the single direct structural target for telomeric induced p53 activation. It is worth mentioning that in the present experiments we have used a circular intact plasmid that is most likely not to be regarded by the cell as damaged DNA. It is therefore not surprising that the extreme C-terminus of the p53 protein, which is referred to as the molecular domain that senses damaged DNA (22,35), is dispensable in the telomeric-induced p53-activation pathway. TR-activated p53 is probably not a mere result of the interaction of p53 with aberrant DNA sequences.

Another possibility for a direct interaction between p53 and telomeric DNA may involve the p53 ‘core’ domain. This assumption is supported by the existence of partial sequence similarity between the consensus p53 binding sequence (5'-PuPuPuC(A/T)(T/A)GPpPyPy-3') that is recognized by the ‘core’ domain (21) and the (TTAGGTTAGG)ₙ telomeric motif. Such a homology may permit the direct interaction of the p53 ‘core’ domain and the TR motif. Under such circumstances it is possible that either the C-terminus and/or the core domain of p53, even at low binding affinity, may activate sequence-specific DNA recognition and enhance p53 transcriptional activity. Although there are no reports claiming that interaction of the p53 ‘core’ domain with DNA leads to p53 stabilization, the possibility that following interaction with telomeric DNA, the p53 molecule undergoes a specific conformational change that renders it resistant to Mdm-2-mediated degradation cannot be excluded.

Participation of several DNA damage inducible and DNA repair proteins such as ATM, DNA-PK, PARP, Ku, Blm and Wri both in the telomere integrity sensing and p53 activity modulation provides strong evidence towards a possible way by which telomere signals are transmitted to p53 (23,41). Indeed, stabilization of p53 following transfection of cells with plasmids containing TRs strongly referred to the involvement of post-translational modifications in the activation process. Introduction of extra-chromosomal DNA containing TRs into cells may initiate a DNA damage checkpoint. Activation of p53 by extra-chromosomal TRs could be described by competition with native telomeres for telomere binding proteins such as TRF-1 and TRF-2. It was shown that exposure of native chromosomal ends caused by squelching out of TRF-2 triggers p53 activation through ATM (17).

Our observation of a p53-dependent reduction in colony formation coupled with the induction of WAF-1 expression observed as a result of extra-chromosomal TR transfection, points to the possibility that enhancement in transactivation potential and p53 protein stabilization are specific stages in the signaling cascade culminated in this physiological response of growth suppression. This p53-dependent growth suppression could be the result of p53-mediated growth arrest and/or apoptosis. In addition, this finding of p53 signaling cells to undergo growth arrest may be the result of telomeric shortening occurring with aging and thus could potentially be a potent anti-cancer protection mechanism.

Previously, it was shown that transfection of cells with linearized exogenous DNA containing TRs at one terminus induces chromosome breakage and de novo telomere formation at the site of the break (53–55). The free DNA ends and double-stranded chromosomal breakage generated were suggested to induce a p53 response (24,73). The mechanism, by which circular plasmid-containing TRs cause in our hands a reduction in colony formation assayed by the long-term growth assay, is still to be determined.

In conclusion, we would like to put forward the hypothesis that p53-dependent growth inhibition induced by the presence of extra-chromosomal telomeric sequences could explain the low frequency of the ALT mechanism. The precise mechanism of ALT is not known, but it could include homologous recombination between endogenous telomeres and/or extra-chromosomal DNA containing telomeric sequences (74–77). Indeed, the immortalized cell lines that use the ALT pathway have either p53 deletion or inactivation of p53 by oncogenes (48,51,78–81). As telomeres, telomerase and p53 are believed to be the target for future therapeutics in aging-associated and malignant disorders, understanding of their interrelationship is expected to have a significance impact on basic research and its clinical implications.

ACKNOWLEDGEMENTS

This work was supported in part by grants from the Israel–USA Binational Science Foundation (BSF) and the Deutsch–Israelische Projektkooperation (DIP) and the Kadoorie Foundation. V.R. is the incumbent of the Norman and Helen Asher Professorial Chair in Cancer Research at the Weizmann Institute.

REFERENCES


